IL-6 was significantly increased in the tumor-bearing control, and the everolimus treatment alone or in combination with CDD866 significantly reduced IL-6, but the CDD866 treatment alone did not show a significant effect on IL-6 (Fig. 11a). This evidence concerns the gene IL6 and neoplasm.